Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0.109. It has been cited 1 time, with 1 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.104
From this paper's citation signal
Citation Network Contribution
5.47 × 10⁻³
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 1 citer.
Comprehensive Cancer Center at Wake Forest Baptist Medical Center
FWCI
0.18
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals